Success Story: Thanks to Our Assistance, a Cellular and Molecular Immunology Researcher Secured NIW Approval Without an RFE
Client’s Testimonial:
“Chen's extensive data and experience helped them adjust effectively to heightened USCIS scrutiny. While the workflow isn't flawless, their strategy works—I definitely recommend them.”
On September 3rd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Student in the Field of Cellular and Molecular Immunology (Approval Notice).
General Field: Cellular and Molecular Immunology
Position at the Time of Case Filing: Graduate Student
Country of Origin: Germany
Country of Residence at the Time of Filing: Germany
Approval Notice Date: September 3rd, 2026
Processing Time: 2 months, 4 days (Premium Processing Upgrade Requested)
Case Summary:
The client’s work focuses on cellular and molecular immunology, immune responses, infectious disease research, and the development of potential therapeutic strategies. Through the exceptional ability pathway, the client sought NIW classification based on a strong record of research achievement, professional recognition, and plans to continue advancing work in an important area of biomedical research. With a background in clinical medicine, the client has conducted research involving immune mechanisms, disease-related protection, and the development of improved approaches to understanding and treating complex health conditions.
The petition explained that this research addresses a significant public health need rather than a purely academic question. The client’s proposed endeavor was to continue applying advanced research methods to study disease-related biological processes and support the development of more effective, targeted therapeutic strategies.
The client had secured an upcoming research role in a U.S.-based biomedical research institute, where he would continue investigating immune responses, tissue barriers, and disease-related immune mechanisms. This planned work aligned closely with the proposed endeavor and helped show that the client was positioned to continue advancing the same field of research in the United States.
To show that the client was well positioned to advance this endeavor, the petition relied on a substantial record of scholarly output, citation impact, peer recognition, and expert support. The client’s record included 6 peer-reviewed journal articles, 3 preprints, 1,052 citations, and at least 11 completed peer reviews for journals in immunology and related fields. Rather than presenting these figures as automatically persuasive, the petition explained how they reflected meaningful reliance by other researchers and professional recognition within cellular and molecular immunology.
The petition also documented research funding from major biomedical sources, including support connected to the National Institute of Allergy and Infectious Diseases (NIAID), the Howard Hughes Medical Institute (HHMI), and the National Center for Advancing Translational Sciences (NCATS). These fundings served as additional evidence that recognized organizations had considered the client’s research sufficiently valuable and credible to warrant financial support, while also demonstrating access to the resources necessary to continue advancing his proposed endeavor.
The petition further demonstrated the client’s significance by showing that other researchers had relied on his work in cellular and molecular immunology and related areas of biomedical research. Several of the client’s papers ranked among the most highly cited Immunology articles for their publication years, including 3 papers in the top 1%, 2 papers in the top 10%, and 1 paper in the top 20%. These comparisons helped place the citation record in context and showed that the client’s work had received recognition beyond ordinary publication.
The case was also supported by 2 recommendation letters from experts in the field. These letters helped explain the client’s technical role in advancing immune memory and antibody evolution research, while also connecting his record to the broader need for improved infectious disease therapeutics and public health strategies. One expert noted:
“There is thus no doubt that [Client] will continue to produce impactful work that benefits public well-being on a global scale.”
With a premium processing upgrade requested, the client’s I-140 NIW petition was approved without a Request for Evidence in 2 months and 4 days. This approval reflects the successful presentation of a case grounded in cellular and molecular immunology expertise, substantial citation impact, independent scholarly reliance, peer-review recognition, expert support, and the national importance of advancing biomedical innovation in the United States.